Pharmacologic aspects of new antiretroviral drugs

Current HIV/AIDS Reports

Volumn 6, Issue 1, 2009, Pages 43-50

  Long, Mary C ^b   King, Jennifer R ^b   Acosta, Edward P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ASTEMIZOLE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CISAPRIDE; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERGOT DERIVATIVE; ETRAVIRINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MIDAZOLAM; NEVIRAPINE; PIMOZIDE; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TERFANIDINE; TIPRANAVIR; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; OXAZINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE; SULFONAMIDE;

ALLERGIC REACTION; AREA UNDER THE CURVE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; FEVER; FOOD; HEADACHE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MYOPATHY; NAUSEA; POPULATION; PRACTICE GUIDELINE; PROTEIN BINDING; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; CLASSIFICATION; DRUG COMBINATION; VIROLOGY;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; OXAZINES; PHOSPHONIC ACIDS; PRACTICE GUIDELINES AS TOPIC; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SULFONAMIDES;

EID: 61449109145     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-009-0007-y     Document Type: Review

References (50)

1. •• Perno CF, Moyle G, Tsoukas C, et al.: Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008, 80:565-576. Thorough review of the causes of antiretroviral resistance, treatment of drug-resistant patients, and prospects for new antiretroviral drugs.
2. •• Department of Health and Human Services; Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 2008. A routinely updated publication with information required for the care and treatment of HIV/AIDS patients, including recommendations for when to start treatment, HAART guidelines for initial therapy, sequencing of drugs in treatment-experienced patients, and treatment guidelines for special populations (eg, pregnant or hepatitis B- or hepatitis C-coinfected patients), including comprehensive tables detailing drug-drug interactions, drug combinations to avoid, and adverse effects.
3. •• Martinez-Cajas JL, Wainberg MA: Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 2008, 68:43-72. Excellent discussion of how to avoid drug resistance through optimal sequencing of available antiretroviral drugs.
4. Bartlett JG: Antiretroviral therapy. In A Guide to Primary Care of People With HIV/AIDS. Edited by Bartlett JG, Cheever LW, Johnson MP, Paauw DS. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau; 2004.
5. • Krakovska O, Wahl LM: Optimal drug treatment regimens for HIV depend on adherence. J Theor Biol 2007, 246:499-509. An analytical approach that uses pharmacokinetic parameters and clinical indicators to model the likelihood of developing drug resistance relative to adherence to a treatment regimen.
6. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
7. •• McCoy C: Darunavir: a nonpeptidic antiretroviral protease inhibitor. Clin Ther 2007, 29:1559-1576. Comprehensive review of darunavir, including clinical pharmacology, resistance mutations development, adverse events, dosing and administration, and pharmacoeconomics.
8. •• Rittweger M, Arasteh K: Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007, 46:739-756. In-depth account of the pharmacologic properties (absorption, distribution, metabolism, excretion), pharmacokinetics, and drug-drug interactions related to darunavir.
9. King JR, Wynn H, Brundage R, Acosta EP: Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 2004, 43:291-310.
10. •• Youle M: Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007, 60:1195-1205. Report of the issues regarding the pharmacologic boosting of protease inhibitors by ritonavir, including the history, pharmacology, discussion of individual drugs, sequencing of protease inhibitors to avoid resistance, and goals of therapy.
11. Ford J, Khoo SH, Back DJ: The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004, 54:982-990.
12. • Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007, 45:761-769. Overview of pharmacokinetics, drug interactions, use in patients, and development of drug resistance related to using tipranavir.
13. Boffito M, Back DJ, Blaschke TF, et al.: Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003, 19:825-835.
14. Schon A, del Mar Ingaramo M, Freire E: The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem 2003, 105:221-230.
15. Clotet B, Bellos N, Molina JM, et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007, 369:1169-1178.
16. Sekar VJ, Lefebvre E, Marien K, et al.: Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007, 29:795-801.
17. • Boffito M, Winston A, Jackson A, et al.: Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007, 21:1449-1455. A novel clinical study evaluating coadministration of two investigational antiretroviral therapies in patients with no other therapeutic options.
18. Smith PF, DiCenzo R, Morse GD: Clinical pharmacokinetics of nonnucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001, 40:893-905.
19. •• Jochmans D: Novel HIV-1 reverse transcriptase inhibitors. Virus Res 2008, 134:171-185. In-depth discussion of the different HIV-1 reverse transcriptase inhibitors that are currently available or in the clinical pipeline, including nucleoside, nonnucleoside, nucleotide, ribonuclease H inhibitors, nucleic acids, and primer/template- competing RT inhibitors.
20. Hodder S: Know your patient: what conditions affect initial HIV treatment success? J Int Assoc Physicians AIDS Care 2008, 7(Suppl 1):S5-S9.
21. •• Back DJ, Burger DM, Flexner CW, Gerber JG: The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005, 39(Suppl 1):S1-S25. Insightful, thorough review of the pharmacologic aspects of nucleoside and nucleotide reverse transcriptase inhibitors that render some members of these classes suitable for once-daily dosing.
22. Reisler R: NNRTI's: New Insights - "The NNRTI TAIL"; drug resistance; prevention of mother-to-child HIV transmission; HAART interruption. In Conference Reports for NATAP. Edited by Levin J. New York: National AIDS Treatment Advocacy Project; 2004:1-3.
23. Gazzard BG, Pozniak AL, Rosenbaum W, et al.: An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003, 17:F49-F54.
24. Magiorkinis E, Paraskevis D, Sambatakou H, et al.: Emergence of an NNRTI resistance mutation Y181C in an HIV-infected NNRTI-naive patient. AIDS Res Hum Retroviruses 2008, 24:413-415.
25. Hachiya A, Kodama EN, Sarafianos SG, et al.: Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008, 82:3261-3270.
26. Andries K, Azijn H, Thielemans T, et al.: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:4680-4686.
27. Poveda E, Garrido C, de Mendoza C, et al.: Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007, 60:1409-1410.
28. Vingerhoets J, Azijn H, Fransen E, et al.: TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005, 79:12773-12782.
29. Intelence (etravirine) [package insert]. Mechelen, Belgium: Tibotec; 2008.
30. Lazzarin A, Campbell T, Clotet B, et al.; DUET-2 Study Group: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:39-48.
31. Madruga JV, Cahn P, Grinsztejn B, et al.; DUET-1 Study Group: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:29-38.
32. Otto MJ: New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr Opin Pharmacol 2004, 4:431-436.
33. Anderson PL, Kakuda TN, Lichtenstein KA: The cellular pharmacology of nucleoside- and nucleotide-analogue reverse transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004, 38:743-753.
34. Piliero PJ: Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004, 37:S2-S12.
35. Ofotokun I, Acosta EP, Lennox JL, et al.: Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 2007, 47:106-119.
36. Marier JF, Dimarco M, Guilbaud R, et al.: Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. J Clin Pharmacol 2007, 47:1381-1389.
37. Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251-260.
38. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al.: Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006, 43:509-515.
39. Iwamoto M, Wenning LA, Petry AS, et al.: Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008, 83:293-299.
40. Isentress (raltegravir) tablets [package insert]. Whitehouse Station, NJ: Merck & Co.; 2007.
41. Kassahun K, McIntosh I, Cui D, et al.: Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007, 35:1657-1663.
42. Levin J: Raltegravir FDA safety report 2007. Available at http://www.natap.org/2007/HIV/083107-07.htm. Accessed March 2008.
43. Grinsztejn B, Nguyen BY, Katlama C, et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269.
44. •• Murray JM, Emery S, Kelleher AD, et al.: Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007, 21:2315-2321. Interesting analysis of the decay kinetics of HIV-1 in light of the rapid decay kinetics of raltegravir.
45. Briz V, Poveda E, Soriano V: HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006, 57:619-627.
46. Lalezari JP, Eron JJ, Carlson M, et al.: A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003, 17:691-698.
47. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
48. • Lorenzen T, Stoehr A, Walther I, Plettenberg A: CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1. Eur J Med Res 2007, 12:419-425. Overview of the clinical performance of CCR5 antagonists, including maraviroc, vicriviroc, and aplaviroc.
49. •• Carter NJ, Keating GM: Maraviroc. Drugs 2007, 67:2277-2288. Comprehensive review of the pharmacokinetics, pharmacodynamics, clinical trials, side effects, drug-drug interactions, and resistance mutations related to maraviroc.
50. Selzentry (maraviroc) tablets [package insert]. New York: Pfizer; 2007.